News | Proton Therapy | April 05, 2018

MedStar Georgetown University Hospital begins treatments with the Hyperscan pencil beam scanning system

First Patient Treated on Mevion's S250i Proton Therapy System

April 5, 2018 — Mevion Medical Systems announced the treatment of the first patient in the world on the Mevion S250i Proton Therapy System at MedStar Georgetown University Hospital in Washington, D.C.

Proton therapy is a precise form of radiation therapy that has the potential to reduce the amount of radiation exposure in some cancers. The Mevion system at MedStar Georgetown includes Hyperscan pencil beam scanning (PBS), which improves on existing proton scanning capabilities and enables clinicians to deliver conformal fields faster and with more precision than in the past.

The Hyperscan system utilizes a novel technology, the Adaptive Aperture, a proton multi-leaf collimator (pMLC), to achieve sharp lateral dose gradients. Multi-leaf collimators are common to conventional radiation therapy and were a key enabling technology to make intensity modulated radiation therapy (IMRT) possible. Mevion’s Adaptive Aperture pMLC is unique to proton therapy, according to the company, designed to protect sensitive organs at every energy layer of the treatment.

In addition to MedStar Georgetown, the Mevion S250i system is under active installation at centers throughout the U.S. and Europe. Two more Hyperscan centers will be treating patients by the end of 2018. An additional two centers are in the construction planning phase, both of which are instances of existing sites adding a second treatment room.

At Medstar Georgetown, the proton system is integrated directly to the hospital as part of a renovation to the existing cancer center entrance. While other proton centers often have to be built as separate standalone facilities, the compact size of the Mevion system enables it to be integrated to existing radiation oncology departments. This can bring significant economic savings to these projects by enabling the centers to share existing support services and personnel throughout the hospital rather than duplicating them in a standalone facility.

Mevion will host a luncheon symposium on Hyperscan PBS and compact proton therapy systems at the annual European Society for Radiotherapy and Oncology (ESTRO) meeting April 21 in Barcelona, Spain. A panel of speakers will be discussing the implementation of these projects and the clinical experiences of the Hyperscan system.

For more information: www.mevion.com

Related Proton Therapy Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy

VIDEO: Mevion Showcases Small Footprint Proton Therapy System

Clinical Considerations for Proton Therapy

VIDEO: Clinical Considerations for Proton Therapy

 

Related Content

News | Nuclear Imaging

December 3, 2021 — Mirion Technologies, Inc., a global provider of detection, measurement, analysis and monitoring ...

Time December 03, 2021
arrow
News | Coronavirus (COVID-19)

December 2, 2021 — Almost two-thirds of U.S. states failed to prioritize cancer patients for COVID-19 vaccinations ...

Time December 02, 2021
arrow
Videos | Radiation Therapy

Jeffrey T. Chapman, a medical student at the University of Texas Southwestern Medical Center, Explains how watching ...

Time November 24, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
Videos | Radiation Therapy

The Elekta Harmony radiotherapy system gained FDA clearance in the summer of 2021 and was on display for the first time ...

Time November 17, 2021
arrow
News | Radiation Therapy

November 17, 2021 — Radiation can be a powerful cancer therapy, but it doesn’t work for everyone. A new study identifies ...

Time November 17, 2021
arrow
Videos | Radiation Oncology

This is a model of the Toshiba ion beam radiation therapy system at the American Society of Radiation Oncology (ASTRO) ...

Time November 16, 2021
arrow
News | Prostate Cancer

November 16, 2021 — A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 ...

Time November 16, 2021
arrow
Videos | Radiation Oncology

Walter Curran, Jr. M.D., FACR, FASCO, GenesisCare global chief medical officer, discusses three technologies that are ...

Time November 16, 2021
arrow
Videos | Radiation Oncology

This is an example of a multileaf collimator (MLC) on the Accuray Thomotherapy radiation therapy system at the American ...

Time November 16, 2021
arrow
Subscribe Now